Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams…
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams…
The Elite Cyber Defenders program combines Nozomi Networks AI-powered OT and IoT monitoring and detection…
The Elite Cyber Defenders program combines Nozomi Networks AI-powered OT and IoT monitoring and detection…
Help support a Philippine banana farm and its surrounding community by playing Lucky Farmer on…
Help support a Philippine banana farm and its surrounding community by playing Lucky Farmer on…
Port Orange, Florida–(Newsfile Corp. – April 25, 2023) – Angelic Lift (386-855-8633), a medical clinic…
TOKYO, Apr 25, 2023 – (JCN Newswire) – Fujitsu ND Solutions AG (“ND Solutions”), a…
NEW YORK–(BUSINESS WIRE)–KKR Real Estate Finance Trust Inc. (“KREF”) (NYSE: KREF) today reported its first…
TOKYO, Apr 25, 2023 – (JCN Newswire) – Hitachi, Ltd. (TSE: 6501) is promoting a…
TOKYO, Apr 25, 2023 – (JCN Newswire) – Hitachi, Ltd. and Equinix Inc. today signed…
HONG KONG, Apr 25, 2023 – (ACN Newswire) – Forward Fashion (International) Holdings Company Limited…
LOS ANGELES–(BUSINESS WIRE)–RBB Bancorp (NASDAQ:RBB) announced today the appointment of Messrs. Robert Franko and Scott…
HOUSTON–(BUSINESS WIRE)–$HESM–Hess Midstream LP (NYSE: HESM) (“Hess Midstream”), today announced that the Board of Directors…
RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and…
Helping school districts mitigate ransomware attacks and improve records request compliance. COLUMBUS, Ohio–(BUSINESS WIRE)–Intellinetics, Inc….
100% OF PATIENTS SAW NO INCREASE IN LEVEL OF SEVERITY, QUICK DECREASE IN SYMPTOMS AFTER…
100% OF PATIENTS SAW NO INCREASE IN LEVEL OF SEVERITY, QUICK DECREASE IN SYMPTOMS AFTER…
NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug…
NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug…